P. Mozafari, S. A. Ibrahim, A. A. Pawar, Z. I. O. Ali, and A. S. Nair, “Balancing Long-Term Efficacy and Immunological Safety: Serious Infection Risk during Extended Ocrelizumab Therapy in Multiple Sclerosis”, JR, vol. 4, no. 2, pp. 57–69, Jul. 2026.